Latest News for Elevate Uranium Stock (OTC:ELVUF)

Elevate Uranium Ltd is engaged in the exploration and evaluation of a uranium deposit and other minerals.

News

Penny Stocks

Small Cap

Markets

General

BKUCF

BNNLF

BQSSF

ELVUF

GLOBAL ATOMIC CORP by Global Atomic Corp.

GLATF

LTSRF

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Photo by Frédéric Paulussen on Unsplash

Upcoming Uranium, Strategic and Precious Metals Investor Conference - What You Need to Know

ELEVATE URANIUM LTD by Elevate Uranium Ltd.

Elevate Uranium Ltd

<p>Simmons First Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFNC#NASDAQ">SFNC</a>) reported quarterly earnings of $0.32 per share which met the analyst consensus estimate. This is a 13.51 percent decrease over earnings of $0.37 per share from the same period last year.  The company reported quarterly sales of $195.09 million which missed the analyst consensus estimate of $202.35 million by 3.59 percent.  This is a 12.78 percent decrease over sales of $223.67 million the same period last year.</p>


Earnings

Earnings Misses

SFNC

Simmons First Ntl Q1 Adj $0.32, Inline, Sales $195.09M Miss $202.35M Estimate

<p>Stifel  analyst Nathan Jones   maintains Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) with a Buy and raises the price target from $150 to $157.</p>


Price Target

Analyst Ratings

Stifel Maintains Buy on Crane, Raises Price Target to $157

<p>In April 2024, the Company purchased the remaining authorized amount of common stock under the existing three-year,&nbsp;$2 billion&nbsp;stock repurchase plan.&nbsp;</p>


Buybacks

Amphenol Plans New Three-year, $2B Open Market Stock Repurchase Program

<p>Ribbon Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.  The company reported quarterly sales of $179.664 million which missed the analyst consensus estimate of $185.029 million by 2.90 percent.  This is a 3.49 percent decrease over sales of $186.159 million the same period last year.</p>


RBBN

Ribbon Comms Q1 2024 GAAP EPS $(0.01), Inline, Sales $179.664M Miss $185.029M Estimate

<p>Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) today announced it has been awarded a deep water integrated multi-well construction contract by Rhino Resources Ltd., a private company engaged in both onshore and offshore energy exploration in Africa.</p>
<p>"This collaboration between Halliburton and Rhino Resources marks a strategic milestone to harness the full potential of Namibia's oil and gas sector," said Jean Marc Lopez, senior vice president, Europe, Eurasia, and Sub-Saharan Africa at Halliburton. "Halliburton, with its collaborative approach and solutions engineering, is uniquely positioned to maximize asset value in this block with Rhino Resources. Together, we will establish a standard for innovation and economic growth in the industry."</p>
<p>Under this agreement, Halliburton will provide complete solutions to construct exploration and appraisal wells, along with testing services. Halliburton will also extend its country operation facilities to support all product service lines from Namibia to enhance collaboration and maximize asset value for Rhino Resources and Namibian customers.</p>
<p>With more than a decade of exploration in Namibia, Rhino Resources holds operatorship of Block 2914A (PEL 85). This block, located in the shallower portion of the Orange Basin, boasts significant potential. It is strategically located less than 20km from the nearest discovery and amidst multiple Namibian discoveries made over the last two years. The block's proximity to other international operators further underscores its strategic relevance.</p>
<p>In late 2022, Rhino conducted a 3D seismic survey that reinforced the block's potential with multiple viable plays and drillable prospects. In addition, Halliburton and Rhino Resources will uphold the emphasis on localization in Namibia's oil and gas sector, with the aim to distribute the economic advantages of Namibia's resources to the local community.</p>
<p>"Rhino is pleased to have established a collaboration with Halliburton and views this as an important driver in the continued growth of the Namibian oil and gas industry," said Travis Smithard, chief executive officer at Rhino Resources Ltd. "The opportunity for catalysing local services and the broadening of positive economic influence in Namibia are expected to establish a valuable legacy for the Namibian people well beyond our initial exploration campaign."</p>
<p>As Halliburton and Rhino Resources approach operational commencement in the fourth quarter of 2024, the agreement underscores the importance of integration of global expertise with local resources to foster economic resilience and progress in Namibia's growing energy sector.</p>


Contracts

Rhino Resources and Halliburton To Sign Contract For Integrated Deep-Water Services Offshore Namibia; No Financial Terms Disclosed

Offerings

SCLX

Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share

<p>Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) reported quarterly Adj earnings of $0.80 per share which beat the analyst consensus estimate of $0.73 by 9.59 percent. The company reported quarterly sales of $3.256 billion which beat the analyst consensus estimate of $3.097 billion by 5.12 percent. This is a 9.48 percent increase over sales of $2.974 billion the same period last year.</p>


Amphenol Q1 2024 Adj EPS $0.80 Beats $0.73 Estimate, Sales $3.256B Beat $3.097B Estimate

<p><strong>Texas Instruments Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported upbeat earnings for its <a href="https://www.benzinga.com/quote/TXN/earnings">first quarter on Tuesday</a>.</p>
<p>Texas Instruments reported first-quarter revenue of $3.66 billion, which beat the consensus estimate of $3.611 billion, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The company's top-line results were down 16% on a year-over-year basis and down 10% sequentially as revenue declined across all end markets.</p>
<p>Texas Instruments reported quarterly earnings of $1.20 per share, which beat analyst estimates of $1.08 per share. The company noted that earnings per share included a 10-cent benefit for items that were not in the original guidance.</p>
<p>"Our cash flow from operations of $6.3 billion for the trailing 12 months again underscored the strength of our business model, the quality of our product portfolio and the benefit of 300mm production," said Haviv Ilan, president and CEO of Texas Instruments.</p>
<p>Texas Instruments said it sees second-quarter revenue to be in the range of $3.65 billion to $3.95 billion versus estimates of $3.77 billion. The company anticipated second-quarter earnings in the range of $1.05 to $1.25 per share versus estimates of $1.16 per share.</p>
<p>Texas Instruments shares gained 1.3% to close at $165.47 on Tuesday.</p>
<p>These analysts made changes to their price targets on Texas Instruments following earnings announcement.</p>
<ul>
<li><strong>Mizuho</strong> boosted the price target on Texas Instruments from $164 to $170. Mizuho analyst Vijay Rakesh maintained a Neutral rating.</li>
<li><strong>Truist Securities</strong> raised the price target on Texas Instruments from $165 to $167. Truist Securities analyst William Stein maintained a Hold rating.</li>
</ul>
<p>Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38396543/meta-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-streets-mos">Meta Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></p>


Trading Ideas

Texas Instruments Analysts Increase Their Forecasts After Upbeat Earnings

<p>Analysts' ratings for United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) over the last quarter vary from bullish to bearish, as provided by 18 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $156.83, a high estimate of $180.00, and a low estimate of $100.00. Surpassing the previous average price target of $156.75, the current average has increased by 0.05%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713960092_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of United Parcel Service by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Schneeberger</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$157.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Oliver Holmes</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Amit Mehrotra</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$179.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>J. Bruce Chan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Helane Becker</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Parash Jain</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Hold</td>
<td>$150.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jonathan Chappell</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$154.00</td>
<td>-</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Scott Schneeberger</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Benjamin Hartford</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Patrick Tyler Brown</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$160.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Parcel Service. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of United Parcel Service compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for United Parcel Service's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of United Parcel Service's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UPS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on United Parcel Service analyst ratings.</strong></a></p>
<h2>Get to Know United Parcel Service Better</h2>
<p>As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 64% of total revenue while international package makes up 20%. Air and ocean freight forwarding, truckload brokerage, and contract logistics make up the remainder. UPS is currently pursuing "strategic alternatives" for its truck brokerage unit, Coyote, which it acquired in 2015.</p>
<h3>Breaking Down United Parcel Service's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining United Parcel Service's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-7.83%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> United Parcel Service's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.44%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> United Parcel Service's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.8%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> United Parcel Service's ROA excels beyond industry benchmarks, reaching <strong>2.27%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.54</strong>, United Parcel Service adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where United Parcel Service Stands With Analysts

<p>Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) reported quarterly earnings of $2.49 per share which missed the analyst consensus estimate of $2.58 by 3.49 percent. This is a 25 percent decrease over earnings of $3.32 per share from the same period last year.  The company reported quarterly sales of $3.004 billion which missed the analyst consensus estimate of $3.046 billion by 1.39 percent.  This is a 3.10 percent decrease over sales of $3.100 billion the same period last year.</p>


Norfolk Southern Q1 2024 Adj EPS $2.49 Misses $2.58 Estimate, Sales $3.004B Miss $3.046B Estimate

<p>Roth MKM  analyst Scott Searle   maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and lowers the price target from $50 to $43.</p>


CALX

Roth MKM Maintains Buy on Calix, Lowers Price Target to $43

<p>During the last three months, 7 analysts shared their evaluations of Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Polaris and provided 12-month price targets. The average target is $100.57, accompanied by a high estimate of $120.00 and a low estimate of $80.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.88%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713960081_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Polaris. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Macgregor</td>
<td>Longbow Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Perry</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon Rolle</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$103.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Tristan Thomas-Martin</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$96.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Polaris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Polaris compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Polaris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Polaris's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PII/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Polaris analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Polaris</h2>
<p>Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to new segments of the outdoor lifestyle market. Polaris products retailed through more than 2,500 dealers in North America and through 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.</p>
<h3>Polaris: A Financial Overview</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Polaris's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-4.78%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Polaris's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.52%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Polaris's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.52%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Polaris's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.84%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.45</strong>, Polaris faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


7 Analysts Have This To Say About Polaris

<p><i>FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor</i><br /><br />&nbsp;</p>
<p><i>Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful</i></p>


Biotech

SCPH

scPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection

<p>Analysts' ratings for Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $147.0, a high estimate of $155.00, and a low estimate of $135.00. This current average has increased by 0.22% from the previous average price target of $146.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713960066_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Quest Diagnostics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Quest Diagnostics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Quest Diagnostics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DGX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Quest Diagnostics analyst ratings.</strong></a></p>
<h2>Discovering Quest Diagnostics: A Closer Look</h2>
<p>Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.</p>
<h3>Quest Diagnostics's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Quest Diagnostics's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-1.93%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.39%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.02%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.4%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Quest Diagnostics's debt-to-equity ratio is below the industry average at <strong>0.87</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 5 Takes On Quest Diagnostics

<p>Analysts' ratings for Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $586.0, a high estimate of $621.00, and a low estimate of $547.00. Witnessing a positive shift, the current average has risen by 2.11% from the previous average price target of $573.89.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713960057_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Elevance Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$585.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$574.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$605.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$557.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$604.00</td>
<td>$602.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$621.00</td>
<td>$584.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$580.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$557.00</td>
<td>$561.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$580.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$584.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$580.00</td>
<td>$547.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$547.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Elevance Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Elevance Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Elevance Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Elevance Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ELV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Elevance Health analyst ratings.</strong></a></p>
<h2>Delving into Elevance Health's Background</h2>
<p>Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.</p>
<h3>A Deep Dive into Elevance Health's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Elevance Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.96%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>5.28%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Elevance Health's ROE excels beyond industry benchmarks, reaching <strong>5.62%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Elevance Health's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.03%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.65</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Decoding 13 Analyst Evaluations For Elevance Health

<p>Throughout the last three months, 21 analysts have evaluated Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $153.33, a high estimate of $200.00, and a low estimate of $110.00. This current average reflects an increase of 12.23% from the previous average price target of $136.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713960040_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Airbnb. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$127.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$168.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$131.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$143.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Mario Lu</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Airbnb. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Airbnb compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Airbnb's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Airbnb's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ABNB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Airbnb analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Airbnb</h2>
<p>Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb's platform offered 7.7 million active accommodation listings as of Dec. 31, 2023. Listings from the company's over 5 million hosts are spread over almost every country in the world. In 2023, 50% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.</p>
<h3>Airbnb's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Airbnb displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>16.61%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Airbnb's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-15.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Airbnb's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-4.04%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Airbnb's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.66%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.28</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ABNB

Analyst Ratings For Airbnb

<p>Ratings for Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $71.25, with a high estimate of $78.00 and a low estimate of $59.00. This current average reflects an increase of 8.78% from the previous average price target of $65.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713960025_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Enova International by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$59.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$73.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Enova International. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Enova International compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Enova International's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Enova International's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ENVA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Enova International analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Enova International</h2>
<p>Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and the United Kingdom. Consumers apply for credit online, receive a decision almost immediately, and can receive funds within one day. Enova acts as either the lender or a third-party facilitator between borrowers and other lenders. The company earns revenue from interest income, finance charges, and other fees, including fees on the transactions between borrowers and third-party lenders. The majority of revenue comes from the United States. The company realizes similar amounts of revenue from each of its three different products: short-term loans, lines of credit, and installment loans.</p>
<h3>Financial Insights: Enova International</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Enova International's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>20.04%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Enova International's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>5.96%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.78%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Enova International's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.8%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Enova International's debt-to-equity ratio is below the industry average at <strong>2.4</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ENVA

Expert Outlook: Enova International Through The Eyes Of 4 Analysts

<p>Truist Securities  analyst William Stein   maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Hold and lowers the price target from $176 to $162.</p>


TSLA

Truist Securities Maintains Hold on Tesla, Lowers Price Target to $162

WIIM

Equinox Gold shares are trading lower after the company announced that it entered into a binding share purchase agreement with funds managed by Orion Mine Financing Management to acquire 40% interest in Greenstone Gold Mine GP.

<p>Truist Securities  analyst William Stein   maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Hold and raises the price target from $165 to $167.</p>


-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Elevate Uranium Stock (OTC:ELVUF)

Monday, October 18, 2021